Your browser doesn't support javascript.
loading
Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez, F V; Alarcón, Mª D L; Mayoral, V; de Madariaga, M; Margarit, C; Duran, J A; Martín-Arroyo, J M T; Carregal, A.
Afiliação
  • Estévez FV; Pain Unit, Consorcio Hospital Provincial de Castellón, Castellón, Spain. franvilles@hotmail.com.
  • Alarcón MDL; Pain Unit, Hospital General Universitario de Valencia, Valencia, Spain.
  • Mayoral V; Pain Unit, Hospital Universitari de Bellvitge, Barcelona, Spain.
  • de Madariaga M; Pain Unit, Hospital Universitario Infanta Sofía, Madrid, Spain.
  • Margarit C; Pain Unit, Hospital General Universitario de Alicante, Alicante, Spain.
  • Duran JA; Pain Unit, Hospital Universitario Nuestra Señora de Candelaria, Hospital en Santa Cruz de Tenerife, Tenerife, Spain.
  • Martín-Arroyo JMT; Pain Unit, Hospital Puerta del Mar, Cádiz, Spain.
  • Carregal A; Pain Unit, Complexo Hospitalario Universitario de Vigo (CHUVI), Pontevedra, Spain.
Clin Transl Oncol ; 21(9): 1168-1176, 2019 Sep.
Article em En | MEDLINE | ID: mdl-30783918
PURPOSE: Current evidence suggests the need to improve the management of breakthrough cancer pain (BTcP). For this reason, we aimed to assess the opinion of a panel of experts composed exclusively of physicians from pain units, who play a major role in BTcP diagnosis and treatment, regarding the key aspects of BTcP management. METHODS: An ad hoc questionnaire was developed to collect real-world data on the management of BTcP. The questionnaire had 5 parts: (a) organizational aspects of pain units (n = 12), (b) definition and diagnosis (n = 3), (c) screening (n = 3), (d) treatment (n = 8), and (e) follow-up (n = 7). RESULTS: A total of 89 pain-unit physicians from 13 different Spanish regions were polled. Most of them agreed on the traditional definition of BTcP (78.9%) and the key features of BTcP (92.1%). However, only 30.3% of participants used the Davies' algorithm for BTcP diagnosis. Respondents preferred to prescribe rapid-onset opioids [mean 77.0% (SD 26.7%)], and most recommended transmucosal fentanyl formulations as the first option for BTcP. There was also considerable agreement (77.5%) on the need for early follow-up (48-72 h) after treatment initiation. Finally, 65.2% of participants believed that more than 10% of their patients underused rapid-onset opioids. CONCLUSIONS: There was broad agreement among pain experts on many important areas of BTcP management, except for the diagnostic method. Pain-unit physicians suggest that rapid-onset opioids may be underused by BTcP patients in Spain, an important issue that need to be evaluated in future studies.
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Dor Irruptiva / Manejo da Dor / Dor do Câncer / Analgésicos Opioides / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Padrões de Prática Médica / Dor Irruptiva / Manejo da Dor / Dor do Câncer / Analgésicos Opioides / Neoplasias Tipo de estudo: Diagnostic_studies / Etiology_studies / Observational_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Clin Transl Oncol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Espanha País de publicação: Itália